Tackling the blind spot of poor-quality medicines in Universal Health Coverage

Figures & data

Table 1 Impact of poor-quality medicines from modelling studies (as obtained from a rapid-review of published literature)

Table 2 Estimated costs of selected commercially-available technologies for the determination of medicine quality

Table 3 Investments in selected technologies for the detection of SF medicines under three investment scenarios for all public secondary or tertiary hospitals cost at most 1% of the 2019 budget and, at a maximum of 0.3% of estimated economic losses due to SF antimalarials, represent savings for Congo, Nigeria and Uganda

Renschler JP, Walters KM, Newton PN, Laxminarayan R. Estimated under-five deaths associated with poor-quality antimalarials in sub-Saharan Africa. Am J Trop Med Hyg. 2015;92(6 Suppl):119–126.

 PubMed Web of Science ®Google Scholar

WHO. A study on the public health and socioeconomic impact of substandard and falsified medical products. WHO. [cited 2020 Feb 4]. Available from: http://www.who.int/medicines/regulation/ssffc/publications/se-study-sf/en/.

 Google Scholar

Ozawa S, Evans DR, Bessias S, Haynie DG, Yemeke TT, Laing SK, et al. Prevalence and Estimated Economic Burden of Substandard and Falsified Medicines in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis. JAMA Netw Open. 2018;1(4):e181662.

 PubMed Web of Science ®Google Scholar

National Academies of Sciences E and Medicine. Crossing the Global Quality Chasm: Improving Health Care Worldwide. Washington, DC: The National Academies Press; 2018. Available from: https://www.nap.edu/catalog/25152/crossing-the-global-quality-chasm-improving-health-care-worldwide.

 Google Scholar

Beargie SM, Higgins CR, Evans DR, Laing SK, Erim D, Ozawa S. The economic impact of substandard and falsified antimalarial medications in Nigeria. PLoS One. 2019;14(8):e0217910.

 PubMed Web of Science ®Google Scholar

Ozawa S, Haynie DG, Bessias S, Laing SK, Ngamasana EL, Yemeke TT, et al. Modeling the Economic Impact of Substandard and Falsified Antimalarials in the Democratic Republic of the Congo. Am J Trop Med Hyg. 2019;100(5):1149–1157.

 PubMed Web of Science ®Google Scholar

Ozawa S, Evans DR, Higgins CR, Laing SK, Awor P. Development of an agent-based model to assess the impact of substandard and falsified anti-malarials: Uganda case study. Malar J. 2019;18(1):5–5.

 PubMedGoogle Scholar

Emmanuel KI. The Access to health care in the Democratic Republic of Congo: Major challenge for the poor. J Nurs Palliat Care Serv (NPCS). 2016;1:103.

 Google Scholar

Federal Ministry of Health. Nigeria Health Facility Registry. 2019 [cited 2020 Feb 4]. Available from: https://hfr.health.gov.ng/statistics/tables.

 Google Scholar

Ministry of Health, Republic of Uganda. Hospitals | Ministry of Health [Internet]. [cited 2020 Feb 4]. Available from: https://health.go.ug/hospitals.

 Google Scholar

Bertone MP, Lurton G, Mutombo PB. Investigating the remuneration of health workers in the DR Congo: implications for the health workforce and the health system in a fragile setting. Health Policy Plan. 2016;31(9):1143–1151.

 PubMed Web of Science ®Google Scholar

Ubaka CM, Ochie UM, Adibe MO. Student pharmacists’ career choices: a survey of three Nigerian schools of pharmacy. Pharm Pract (Granada). 2013;11(3):149–155.

 PubMedGoogle Scholar

Availability of data and materials

Not applicable.